Pure Global AI
NCT05767723Recruiting

Platelet Sub-study of the Neomindset Trial

Platelet Function Evaluation in Patients With Acute Coronary Syndromes on Potent P2Y12 Inhibitor Monotherapy Versus Dual Antiplatelet Therapy With Aspirin and a Potent P2Y12 Inhibitor
Hospital Israelita Albert EinsteinPhase 4ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Acute Coronary Syndrome
Drug/Device/Intervention
Dual antiplatelet therapy: Acetylsalicylic acid + ticagrelor OR Acetylsalicylic acid + prasugrel
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Hospital Israelita Albert Einstein
Location
São Paulo, Brazil
Timeline & enrollment
Phase
Phase 4
Start date
Feb 06, 2023
End date
Mar 06, 2024
Enrollment
48 participants
Primary outcome

Platelet function using PFA-100

Summary

The general purpose of the Neomindset trial is to evaluate the non-inferiority hypothesis for
 ischemic events and the superiority hypothesis for bleeding events resulting from platelet
 P2Y12 receptor inhibitors given as monotherapy in comparison with conventional dual
 antiplatelet therapy in acute coronary syndrome patients treated with percutaneous coronary
 intervention.
 
 The platelet sub-study will be conducted at the Hospital Israelita Albert Einstein. This
 sub-study will recruit randomized patients from the Neomindset trial to evaluate platelet
 function after at least 30 days of study treatment with either P2Y12 inhibitor monotherapy or
 dual antiplatelet therapy.

ICD-10 classifications
Acute myocardial infarctionAcute myocardial infarction, unspecifiedAcute subendocardial myocardial infarctionAcute ischaemic heart disease, unspecifiedOther acute ischaemic heart diseases
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05767723
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05767723 through Pure Global AI's free database. This Phase 4 trial is sponsored by Hospital Israelita Albert Einstein and is currently Recruiting. The study focuses on Acute Coronary Syndrome. Target enrollment is 48 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.